Acasti Pharma Revenue, Profits - ACST Quarterly Income Statement

Add to My Stocks
$0.67 $0.01 (1.47%) ACST stock closing price Jun 19, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Acasti Pharma stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2017 Q4 impacts the ACST stock. Investors typically check year over year or quarter over quarter revenue growth. The Acasti Pharma profit and loss statement for 2017 Q4 shows a net profit of $-4.8M. Profits for last year was $-3.59M. Apart from this an investor should also check Acasti Pharma assets and Acasti Pharma free cash flow.

View and download details of revenue and profits for Acasti Pharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Acasti Pharma Revenues or Net Sales
---------
Cost Of Goods Sold (COGS)---------
Acasti Pharma Gross Profit
---------
Research & Development Expense----1.26M1.23M1.84M-1.06M
Selling General & Admin Expense---------
Income Before Depreciation Depletion Amortization-----1.89M-1.88M-2.27M--1.99M
Depreciation Depletion Amortization---------
Non Operating Income---------
Interest Expense---------
Acasti Pharma Pretax Income
-----1.8M-1.79M-2.42M--1.66M
Provision for Income Taxes---------
MinorityInterest---------
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-4.8M-3.59M-2.07M-1.96M-1.81M-1.8M-2.43M-1.38M-1.66M
Extraordinary Items & Discontinued Operations---------
Acasti Pharma Profit/ Loss (Net Income)
-4.8M-3.59M-2.07M-1.96M-1.81M-1.8M-2.43M-1.38M-1.66M
Average Shares used to compute Diluted EPS15.25M14.72M14.71M11.3M10.71M10.71M10.71M10.66M10.66M
Average Shares used to compute Basic EPS15.25M14.72M14.71M11.3M10.71M10.71M10.71M10.66M10.66M
Income Before Nonrecurring Items-4.8M-3.59M-2.07M-1.96M-1.81M-1.8M-2.43M-1.38M-1.66M
Income from Nonrecurring Items---------
Acasti Pharma Earnings Per Share Basic Net
-0.31-0.25-0.14-0.17-0.17-0.17-0.23-0.13-0.16
Acasti Pharma Earnings Per Share Diluted Net
-0.31-0.25-0.14-0.17-0.17-0.17-0.23-0.13-0.16
EPS Diluted Before Nonrecurring Items-0.31-0.25-0.14-0.17-0.17-0.17-0.23-0.13-0.16
Preferred Dividends Acc Pd---------
Dividends Common0.00--------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

It is very helpful to read a report on Acasti Pharma stock analysis. An investor must check the following items in an income statement:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Acasti Pharma revenue chart, implies that the company is growing. It has not been the case with Acasti Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. ACST stock had a poor bottom line growth.

The income statement is also called the profit and loss statement. Apart from the ACST income statement, one can check the Acasti Pharma historical stock prices to check how the price has moved with time.

Acasti Pharma Income Statement - Key Financial Ratios

Operating Margin
0
Net Profit Margin
0